利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.026 秒)

    Kit for assessing mitochondrial toxicity
    2.
    发明授权
    Kit for assessing mitochondrial toxicity 失效
    用于评估线粒体毒性的试剂盒

    公开(公告)号：US07718790B2

    公开(公告)日：2010-05-18

    申请号：US11686499

    申请日：2007-03-15

    申请人： Lieven Stuyver ,  Michael J. Otto

    发明人： Lieven Stuyver ,  Michael J. Otto

    IPC分类号： C07H21/04

    CPC分类号： C07H19/06 ,  C07H19/048 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H21/04 ,  C12Q1/6809 ,  C12Q1/6876 ,  C12Q1/689 ,  C12Q1/6895 ,  C12Q1/701 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/158 ,  Y10S435/81 ,  C12Q2561/101 ,  C12Q2545/101 ,  C12Q2537/143

    摘要： Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents.

    摘要翻译： 提供了基于实时PCR同时定量病变细胞中核酸的方法和方法。 实时PCR方案是用于可靠定量体外药物筛选和评估方案以确定潜在的抗病毒剂的功效的优良工具。 在一步实时RT-PCR（Applied Biosystems，CA）中使用这些同时PCR循环阈值（Ct）检测技术的定量消除了由终点RT-PCR产物定量产生的变异性。 此外，线粒体毒性测定是评估这些化学治疗剂的潜在副作用的一个附加工具。

    SIMULTANEOUS QUANTIFICATION OF NUCLEIC ACIDS IN DISEASED CELLS
    3.
    发明申请
    SIMULTANEOUS QUANTIFICATION OF NUCLEIC ACIDS IN DISEASED CELLS 失效
    在细胞中同时检测核酸的量

    公开(公告)号：US20090220950A1

    公开(公告)日：2009-09-03

    申请号：US11949162

    申请日：2007-12-03

    申请人： LIEVEN STUYVER ,  Michael J. Otto

    发明人： LIEVEN STUYVER ,  Michael J. Otto

    IPC分类号： C12Q1/68

    CPC分类号： C07H19/06 ,  C07H19/048 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H21/04 ,  C12Q1/6809 ,  C12Q1/6876 ,  C12Q1/689 ,  C12Q1/6895 ,  C12Q1/701 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/158 ,  Y10S435/81 ,  C12Q2561/101 ,  C12Q2545/101 ,  C12Q2537/143

    摘要： Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents.

    摘要翻译： 提供了基于实时PCR同时定量病变细胞中核酸的方法和方法。 实时PCR方案是用于可靠定量体外药物筛选和评估方案以确定潜在的抗病毒剂的功效的优良工具。 在一步实时RT-PCR（Applied Biosystems，CA）中使用这些同时PCR循环阈值（Ct）检测技术的定量消除了由终点RT-PCR产物定量产生的变异性。 此外，线粒体毒性测定是评估这些化学治疗剂的潜在副作用的一个附加工具。

    N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS
    5.
    发明申请
    N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS 审中-公开
    用于治疗病毒感染的N4-ACYLCYTOSINE NUELEOSIDES

    公开(公告)号：US20120202766A1

    公开(公告)日：2012-08-09

    申请号：US13371654

    申请日：2012-02-13

    申请人： Michael J. Otto ,  Junxing Shi ,  Kyoichi A. Watanabe

    发明人： Michael J. Otto ,  Junxing Shi ,  Kyoichi A. Watanabe

    IPC分类号： A61K31/7068 ,  A61P31/18 ,  A61P31/20 ,  C07H19/06

    CPC分类号： C07H19/06 ,  C07D405/04 ,  C07D409/14 ,  C07H19/16

    摘要： The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

    摘要翻译： 本发明涉及在人类患者或其他动物宿主中治疗或预防病毒感染，特别是人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV）感染）的方法和组合物，包括施用N.sup 4-酰基-2'，3'-二脱氧-5-氟胞苷或N，4-酰基-2'，3'-二脱氧-ω-2'，3'-二脱氧-5-氟胞苷和药学上可接受的 盐，前药和其它衍生物。

    N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS
    6.
    发明申请
    N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS 失效
    用于治疗病毒感染的N4-ACYLCYTOSINE NUELEOSIDES

    公开(公告)号：US20090176730A1

    公开(公告)日：2009-07-09

    申请号：US11969427

    申请日：2008-01-04

    申请人： Michael J. Otto ,  Junxing Shi ,  Kyoichi A. Watanabe

    发明人： Michael J. Otto ,  Junxing Shi ,  Kyoichi A. Watanabe

    IPC分类号： A61K31/7068 ,  C07H19/06 ,  A61P31/18

    CPC分类号： C07H19/06 ,  C07D405/04 ,  C07D409/14 ,  C07H19/16

    摘要： The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

    摘要翻译： 本发明涉及在人类患者或其他动物宿主中治疗或预防病毒感染，特别是人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV）感染）的方法和组合物，包括施用N.sup 4-酰基-2'，3'-二脱氧-5-氟胞苷或N，4-酰基-2'，3'-二脱氢-2'，3'-二脱氧-5-氟胞苷及其药学上可接受的盐， 前药及其衍生物。

    N4-acylcytosine nucleosides for treatment of viral infections
    7.
    发明授权
    N4-acylcytosine nucleosides for treatment of viral infections 失效
    用于治疗病毒感染的N4-酰基胞嘧啶核苷

    公开(公告)号：US07105527B2

    公开(公告)日：2006-09-12

    申请号：US10318511

    申请日：2002-12-13

    申请人： Michael J. Otto ,  Junxing Shi ,  Kyoichi A. Watanabe

    发明人： Michael J. Otto ,  Junxing Shi ,  Kyoichi A. Watanabe

    IPC分类号： C07D239/47 ,  A61K31/513 ,  A61K31/7072 ,  A61P31/18

    CPC分类号： C07H19/06 ,  C07D405/04 ,  C07D409/14 ,  C07H19/16

    摘要： The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acyl-2′,3′-dideoxy-5-fluorocytidine or N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

    摘要翻译： 本发明涉及在人类或其它动物宿主中治疗或预防病毒感染，特别是人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV）感染）的方法和组合物，包括施用N 4'-酰基-2'，3'-二脱氧-5-氟胞苷或N 4 - 酰基-2'，3'-二脱氢-2'，3'-二脱氧-5 - 氟胞苷及其药学上可接受的盐，前药和其它衍生物。

    Laminated container structure incorporating a peelable panel section having a heat transferable image
    9.
    发明授权
    Laminated container structure incorporating a peelable panel section having a heat transferable image 失效
    包括具有可传热图像的可剥离面板部分的层压容器结构

    公开(公告)号：US4308679A

    公开(公告)日：1982-01-05

    申请号：US219008

    申请日：1980-12-22

    申请人： George C. Ray, III ,  Michael J. Otto ,  Charles E. Price

    发明人： George C. Ray, III ,  Michael J. Otto ,  Charles E. Price

    IPC分类号： B65D5/42 ,  G09F3/00

    CPC分类号： B65D5/4225 ,  Y10S206/831

    摘要： A laminated or multiple-ply container structure comprising an inner wall of a substantially rigid material and an outer wall of a thin, generally pliant material, such as a glossy finished paper, adhesively fastened thereto by a suitable adhesive or glue. Formed in the outer wall of the container, as an integral component thereof, and through the intermediary of a tear outline constituted of perforations extending through at least the outer ply or wall is a section constituting a readily removable or peelable coupon-like panel, with the peeling off of the panel adapted to be effectuated without adversely affecting the integrity of the container structure or necessitating the use of special cutting instruments or tools. The outer surface of the removable panel has a heat transferable image imprinted thereon which, after separation of the panel from the container structure, is adapted to be positioned in contact with a suitable transfer surface whereby, through the application of a hot iron, the transferable image which is also commonly referred to as an "iron-on" is imparted to the transfer surface to form a decorative image or imprint thereon.

    摘要翻译： 层压或多层容器结构，其包括基本刚性材料的内壁和薄的，通常柔顺的材料（例如光滑的成品纸）的外壁，通过合适的粘合剂或胶粘合到其上。 形成在容器的外壁中作为其整体部件，并且通过由穿过至少外层或壁延伸的穿孔构成的撕裂轮廓的中间部分是构成容易移除或可剥离的优惠券样面板的部分，其中 适于实现的面板的剥离而不会不利地影响容器结构的完整性或者需要使用特殊的切割工具或工具。 可拆卸面板的外表面具有压印在其上的可传热图像，在将面板与容器结构分离之后，其适于定位成与合适的转移表面接触，由此通过使用热铁，可转印的 通常被称为“熨烫”的图像被赋予转印表面以在其上形成装饰图像或印记。

    Tamper resistant means for on-package peelable premium
    10.
    发明授权
    Tamper resistant means for on-package peelable premium 失效
    防篡改意味着包装上可剥离的溢价

    公开(公告)号：US4306367A

    公开(公告)日：1981-12-22

    申请号：US139045

    申请日：1980-04-10

    申请人： Michael J. Otto

    发明人： Michael J. Otto

    IPC分类号： B65D5/42 ,  G09F3/02 ,  G09F3/00

    CPC分类号： B65D5/4229 ,  G09F3/0292 ,  Y10S206/831 ,  Y10S283/903 ,  Y10S428/914 ,  Y10T428/15

    摘要： In cartons made from laminated packaging material wherein a peelably removable section of the outer ply is defined by a weakened tear line and said section is unadhered to the substrate, resistance to unauthorized tampering or removal of such section from said container is achieved by utilizing a water soluble adhesive as a laminant and including a border area of said section at the starting point of the tear outline within the area of adherence by said laminant to thus require application of moisture to said border area to dissolve said adhesive at said area before the tearing away of such section can be accomplished.

    摘要翻译： 在由层压包装材料制成的纸箱中，外层的可剥离的可拆卸部分由弱化的撕裂线限定，并且所述部分未粘附到基底上，通过利用水来实现对未经授权的擅动或者从所述容器移除这种部分的抵抗力 可溶性粘合剂作为层压剂，并且在所述层压体的粘附区域内包括在撕裂轮廓的起点处的所述区段的边界区域，从而需要在所述边界区域施加水分以在剥离之前在所述区域溶解所述粘合剂 可以实现这一部分。